University of Texas Southwestern Medical Center

Jeffrey A. Cadeddu, MD, Ralph C. Smith, MD, Distinguished Chair in Minimally Invasive Urologic Surgery, Director of The University of Texas (UT) Southwestern Clinical Center for Minimally Invasive Treatment of Urologic Cancer, and Professor of Urology and Radiology at UT Southwestern Medical Center in Dallas, Texas, discusses multiparametric magnetic resonance imaging (mpMRI) for small renal masses (SRM). Dr. Cadeddu emphasizes the use of mpMRI and a clear cell likelihood score (ccLS) as a promising, reliable, non-invasive, and cost-effective means of renal tumor characterization that can eliminate the need for biopsy in most patients.

Jeffrey A.Cadeddu, MD, discusses optimal outcomes in kidney tumor ablation. He reviews reliable and reproducible 5+ year data comparing ablation effectiveness and outcomes to that of surgery and emphasizes that for tumors of <3 cm, tumor ablation is indicated. Dr. Cadeddu explains that ablation is nephron-preserving and minimizes chronic kidney disease progression, is less expensive than conventional surgery, reduces risk of metastatic potential associated with AS, and in addition to tumor size, histologic subtype is an important consideration in treatment decision-making.